Parmax Pharma Limited reported unaudited earnings results for third quarter and nine months ended December 31, 2016. For the quarter, the company’s total income from operations (net) was INR 0.15 million. Net loss was INR 0.03 million compared to INR 0.06 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 0.034 million compared to INR 0.061 million a year ago. Loss from ordinary activities before tax was INR 0.034 million compared to INR 0.061 million a year ago. For the nine months, the company’s total income from operations (net) was INR 0.45 million. Net profit was INR 0.0187. Profit from operations before other income, finance costs and exceptional items was INR 0.0187 million. Loss from ordinary activities before tax was INR 0.0187 million.